JAMA ONCOL 润色咨询

JAMA Oncology

出版年份:暂无数据 年文章数:1010 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:1.9% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享JAMA Oncology的投稿经历,顶刊效率高,回复快,祝大家投稿顺利! 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人,意见非常多且细致,总体均给出了较positive评价,最后编辑给了2-3周时间修回,申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept! 最后也祝大家投稿文章顺利接收!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:大神们,咨询下,这个杂志,投letter接收后,多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2190567, encodeId=b62f219056e1f, content=Comment接受后编辑一般应该邀请原作者回复吧?要好久啊,有没有大神知道啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63015448712, createdName=ms9000001607974484, createdTime=Sat Mar 02 11:44:48 CST 2024, time=2024-03-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2174322, encodeId=d4ea21e432298, content=我也记录一下不知死活的试探,P<0.05,已under review5天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5W6MkhHzB4rOhiabvSueScSM6GPuX13O3OEohngXNuLKIgkpztyRqmWamT6I1KyOJVHD61qHdlRticS2llwhvrCA/132, createdBy=5a555242187, createdName=walkpigcat, createdTime=Mon Dec 11 20:45:16 CST 2023, time=2023-12-11, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向:肺癌;Oncology<br>经验分享:请问大家投稿以后收到杂志的邮件了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2023-05-06 Oncosurgeon-J 来自上海

    审稿速度:3.0 | 投稿命中率:5.0
    偏重的研究方向:肿瘤
    经验分享:分享JAMA Oncology的投稿经历,顶刊效率高,回复快,祝大家投稿顺利! 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人,意见非常多且细致,总体均给出了较positive评价,最后编辑给了2-3周时间修回,申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept! 最后也祝大家投稿文章顺利接收!

    8

    展开8条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享JAMA Oncology的投稿经历,顶刊效率高,回复快,祝大家投稿顺利! 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人,意见非常多且细致,总体均给出了较positive评价,最后编辑给了2-3周时间修回,申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept! 最后也祝大家投稿文章顺利接收!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:大神们,咨询下,这个杂志,投letter接收后,多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2190567, encodeId=b62f219056e1f, content=Comment接受后编辑一般应该邀请原作者回复吧?要好久啊,有没有大神知道啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63015448712, createdName=ms9000001607974484, createdTime=Sat Mar 02 11:44:48 CST 2024, time=2024-03-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2174322, encodeId=d4ea21e432298, content=我也记录一下不知死活的试探,P<0.05,已under review5天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5W6MkhHzB4rOhiabvSueScSM6GPuX13O3OEohngXNuLKIgkpztyRqmWamT6I1KyOJVHD61qHdlRticS2llwhvrCA/132, createdBy=5a555242187, createdName=walkpigcat, createdTime=Mon Dec 11 20:45:16 CST 2023, time=2023-12-11, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向:肺癌;Oncology<br>经验分享:请问大家投稿以后收到杂志的邮件了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2023-03-22 朝天之阙 来自广西

    审稿速度:1.0 | 投稿命中率:75.0
    经验分享:大神们,咨询下,这个杂志,投letter接收后,多久才出proofs

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享JAMA Oncology的投稿经历,顶刊效率高,回复快,祝大家投稿顺利! 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人,意见非常多且细致,总体均给出了较positive评价,最后编辑给了2-3周时间修回,申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept! 最后也祝大家投稿文章顺利接收!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:大神们,咨询下,这个杂志,投letter接收后,多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2190567, encodeId=b62f219056e1f, content=Comment接受后编辑一般应该邀请原作者回复吧?要好久啊,有没有大神知道啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63015448712, createdName=ms9000001607974484, createdTime=Sat Mar 02 11:44:48 CST 2024, time=2024-03-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2174322, encodeId=d4ea21e432298, content=我也记录一下不知死活的试探,P<0.05,已under review5天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5W6MkhHzB4rOhiabvSueScSM6GPuX13O3OEohngXNuLKIgkpztyRqmWamT6I1KyOJVHD61qHdlRticS2llwhvrCA/132, createdBy=5a555242187, createdName=walkpigcat, createdTime=Mon Dec 11 20:45:16 CST 2023, time=2023-12-11, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向:肺癌;Oncology<br>经验分享:请问大家投稿以后收到杂志的邮件了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2024-03-02 ms9000001607974484 来自湖北省

    Comment接受后编辑一般应该邀请原作者回复吧?要好久啊,有没有大神知道啊

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享JAMA Oncology的投稿经历,顶刊效率高,回复快,祝大家投稿顺利! 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人,意见非常多且细致,总体均给出了较positive评价,最后编辑给了2-3周时间修回,申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept! 最后也祝大家投稿文章顺利接收!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:大神们,咨询下,这个杂志,投letter接收后,多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2190567, encodeId=b62f219056e1f, content=Comment接受后编辑一般应该邀请原作者回复吧?要好久啊,有没有大神知道啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63015448712, createdName=ms9000001607974484, createdTime=Sat Mar 02 11:44:48 CST 2024, time=2024-03-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2174322, encodeId=d4ea21e432298, content=我也记录一下不知死活的试探,P<0.05,已under review5天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5W6MkhHzB4rOhiabvSueScSM6GPuX13O3OEohngXNuLKIgkpztyRqmWamT6I1KyOJVHD61qHdlRticS2llwhvrCA/132, createdBy=5a555242187, createdName=walkpigcat, createdTime=Mon Dec 11 20:45:16 CST 2023, time=2023-12-11, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向:肺癌;Oncology<br>经验分享:请问大家投稿以后收到杂志的邮件了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2023-12-11 walkpigcat 来自湖南省

    我也记录一下不知死活的试探,P<0.05,已under review5天了

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享JAMA Oncology的投稿经历,顶刊效率高,回复快,祝大家投稿顺利! 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人,意见非常多且细致,总体均给出了较positive评价,最后编辑给了2-3周时间修回,申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept! 最后也祝大家投稿文章顺利接收!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:大神们,咨询下,这个杂志,投letter接收后,多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2190567, encodeId=b62f219056e1f, content=Comment接受后编辑一般应该邀请原作者回复吧?要好久啊,有没有大神知道啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63015448712, createdName=ms9000001607974484, createdTime=Sat Mar 02 11:44:48 CST 2024, time=2024-03-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2174322, encodeId=d4ea21e432298, content=我也记录一下不知死活的试探,P<0.05,已under review5天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5W6MkhHzB4rOhiabvSueScSM6GPuX13O3OEohngXNuLKIgkpztyRqmWamT6I1KyOJVHD61qHdlRticS2llwhvrCA/132, createdBy=5a555242187, createdName=walkpigcat, createdTime=Mon Dec 11 20:45:16 CST 2023, time=2023-12-11, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向:肺癌;Oncology<br>经验分享:请问大家投稿以后收到杂志的邮件了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2021-01-13 王学谦

    收中药注射液文章吗

    2

    展开2条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享JAMA Oncology的投稿经历,顶刊效率高,回复快,祝大家投稿顺利! 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人,意见非常多且细致,总体均给出了较positive评价,最后编辑给了2-3周时间修回,申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept! 最后也祝大家投稿文章顺利接收!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:大神们,咨询下,这个杂志,投letter接收后,多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2190567, encodeId=b62f219056e1f, content=Comment接受后编辑一般应该邀请原作者回复吧?要好久啊,有没有大神知道啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63015448712, createdName=ms9000001607974484, createdTime=Sat Mar 02 11:44:48 CST 2024, time=2024-03-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2174322, encodeId=d4ea21e432298, content=我也记录一下不知死活的试探,P<0.05,已under review5天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5W6MkhHzB4rOhiabvSueScSM6GPuX13O3OEohngXNuLKIgkpztyRqmWamT6I1KyOJVHD61qHdlRticS2llwhvrCA/132, createdBy=5a555242187, createdName=walkpigcat, createdTime=Mon Dec 11 20:45:16 CST 2023, time=2023-12-11, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向:肺癌;Oncology<br>经验分享:请问大家投稿以后收到杂志的邮件了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2022-10-19 blossom777

    收个案吗 有大神有经验吗😭

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享JAMA Oncology的投稿经历,顶刊效率高,回复快,祝大家投稿顺利! 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人,意见非常多且细致,总体均给出了较positive评价,最后编辑给了2-3周时间修回,申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept! 最后也祝大家投稿文章顺利接收!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:大神们,咨询下,这个杂志,投letter接收后,多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2190567, encodeId=b62f219056e1f, content=Comment接受后编辑一般应该邀请原作者回复吧?要好久啊,有没有大神知道啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63015448712, createdName=ms9000001607974484, createdTime=Sat Mar 02 11:44:48 CST 2024, time=2024-03-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2174322, encodeId=d4ea21e432298, content=我也记录一下不知死活的试探,P<0.05,已under review5天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5W6MkhHzB4rOhiabvSueScSM6GPuX13O3OEohngXNuLKIgkpztyRqmWamT6I1KyOJVHD61qHdlRticS2llwhvrCA/132, createdBy=5a555242187, createdName=walkpigcat, createdTime=Mon Dec 11 20:45:16 CST 2023, time=2023-12-11, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向:肺癌;Oncology<br>经验分享:请问大家投稿以后收到杂志的邮件了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2023-02-23 ms6000001877480263 来自四川省

    偏重的研究方向:肺癌;Oncology
    经验分享:请问大家投稿以后收到杂志的邮件了吗?

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享JAMA Oncology的投稿经历,顶刊效率高,回复快,祝大家投稿顺利! 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人,意见非常多且细致,总体均给出了较positive评价,最后编辑给了2-3周时间修回,申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept! 最后也祝大家投稿文章顺利接收!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:大神们,咨询下,这个杂志,投letter接收后,多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2190567, encodeId=b62f219056e1f, content=Comment接受后编辑一般应该邀请原作者回复吧?要好久啊,有没有大神知道啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63015448712, createdName=ms9000001607974484, createdTime=Sat Mar 02 11:44:48 CST 2024, time=2024-03-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2174322, encodeId=d4ea21e432298, content=我也记录一下不知死活的试探,P<0.05,已under review5天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5W6MkhHzB4rOhiabvSueScSM6GPuX13O3OEohngXNuLKIgkpztyRqmWamT6I1KyOJVHD61qHdlRticS2llwhvrCA/132, createdBy=5a555242187, createdName=walkpigcat, createdTime=Mon Dec 11 20:45:16 CST 2023, time=2023-12-11, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向:肺癌;Oncology<br>经验分享:请问大家投稿以后收到杂志的邮件了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2021-12-27 rayms

    上传文章时应该上传word还是pdf?

    2

    展开2条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享JAMA Oncology的投稿经历,顶刊效率高,回复快,祝大家投稿顺利! 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人,意见非常多且细致,总体均给出了较positive评价,最后编辑给了2-3周时间修回,申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept! 最后也祝大家投稿文章顺利接收!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:大神们,咨询下,这个杂志,投letter接收后,多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2190567, encodeId=b62f219056e1f, content=Comment接受后编辑一般应该邀请原作者回复吧?要好久啊,有没有大神知道啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63015448712, createdName=ms9000001607974484, createdTime=Sat Mar 02 11:44:48 CST 2024, time=2024-03-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2174322, encodeId=d4ea21e432298, content=我也记录一下不知死活的试探,P<0.05,已under review5天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5W6MkhHzB4rOhiabvSueScSM6GPuX13O3OEohngXNuLKIgkpztyRqmWamT6I1KyOJVHD61qHdlRticS2llwhvrCA/132, createdBy=5a555242187, createdName=walkpigcat, createdTime=Mon Dec 11 20:45:16 CST 2023, time=2023-12-11, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向:肺癌;Oncology<br>经验分享:请问大家投稿以后收到杂志的邮件了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2021-12-28 小动量

    文章应该如何上传?

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2130637, encodeId=25b9213063e46, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:分享JAMA Oncology的投稿经历,顶刊效率高,回复快,祝大家投稿顺利! 2022.8.7 submit 2022.8.7 QC 2022.8.8 Under review 2022.10.10 催稿 2022.10.11 邮件回复在等第三个reviewer意见 2022.11.04 一审结果--修回 3个审稿人,意见非常多且细致,总体均给出了较positive评价,最后编辑给了2-3周时间修回,申请延期一周 2022.11.04--11.30 修改论文+润色 2022.12.01 R1 resubmit 2022.12.01 QC 2022.12.02 Under review 2023.1.10 accept! 最后也祝大家投稿文章顺利接收!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160126/IMG56A79212C4AA18639.jpg, createdBy=fadd1683002, createdName=Oncosurgeon-J, createdTime=Sat May 06 22:41:43 CST 2023, time=2023-05-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2121136, encodeId=f1eb212113662, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:大神们,咨询下,这个杂志,投letter接收后,多久才出proofs, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23963312341, createdName=朝天之阙, createdTime=Wed Mar 22 16:29:21 CST 2023, time=2023-03-22, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2190567, encodeId=b62f219056e1f, content=Comment接受后编辑一般应该邀请原作者回复吧?要好久啊,有没有大神知道啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63015448712, createdName=ms9000001607974484, createdTime=Sat Mar 02 11:44:48 CST 2024, time=2024-03-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2174322, encodeId=d4ea21e432298, content=我也记录一下不知死活的试探,P<0.05,已under review5天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/5W6MkhHzB4rOhiabvSueScSM6GPuX13O3OEohngXNuLKIgkpztyRqmWamT6I1KyOJVHD61qHdlRticS2llwhvrCA/132, createdBy=5a555242187, createdName=walkpigcat, createdTime=Mon Dec 11 20:45:16 CST 2023, time=2023-12-11, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=916104, encodeId=2063916104d7, content=收中药注射液文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d4a1696282, createdName=王学谦, createdTime=Wed Jan 13 00:02:30 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094828, encodeId=cc3f2094828b0, content=收个案吗 有大神有经验吗😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=136, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=022e5557503, createdName=blossom777, createdTime=Wed Oct 19 22:14:04 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2116018, encodeId=fe212116018f8, content=偏重的研究方向:肺癌;Oncology<br>经验分享:请问大家投稿以后收到杂志的邮件了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230223/3495061b3fd940bfae63e19d5c634f3e/4aae1a7e9e5c4f4f890a29ff7266640b.jpg, createdBy=0b086152617, createdName=ms6000001877480263, createdTime=Thu Feb 23 01:35:11 CST 2023, time=2023-02-23, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1106766, encodeId=11551106e6640, content=上传文章时应该上传word还是pdf?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:53 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106765, encodeId=8b941106e6535, content=文章应该如何上传?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584746, encodeId=65f1584e4659, content=你会弄了吗<span class="quote">156****8060暂无昵称 2020-01-16 00:00:00 发表:<br>老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议</span>, beContent=156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议, objectType=tool_impact_factor, channel=null, level=null, likeNumber=339, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Fri Feb 14 00:00:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2020-02-14 1e2321c7m65(暂无匿称)

    你会弄了吗156****8060暂无昵称 2020-01-16 00:00:00 发表:
    老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议

    156****8060暂无昵称 2020-01-16 00:00:00 发表: 老师 你好 请问共同作者的版权转让协议怎么写 我注册了共同作者 但是没有找到版权转让协议

    0

共36条页码: 1/4页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分